TY - JOUR AU - Giuliani, Meredith AU - Bezjak, Andrea PY - 2016 TI - Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung carcinoma, radiological suspicion of a local recurrence is not sufficient indication to proceed to salvage therapy JF - Translational Lung Cancer Research; Vol 5, No 6 (December 29, 2016): Translational Lung Cancer Research (Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer) Y2 - 2016 KW - N2 - Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has become the standard of care for inoperable stage I non-small cell lung carcinoma (NSCLC). SBRT for peripheral tumors is well tolerated with minimal side effects (1,2) and results in excellent local control (2). While local recurrence is uncommon following lung SBRT, with the increasing use of SBRT in operable patients, there is a greater need to identify and manage local recurrences. UR - https://tlcr.amegroups.org/article/view/11342